Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: Comparison with interleukin-1-synthesis inhibitors

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 1, 1996, Pages 46-52

  Rainsford, K D ^a,b   Ying, C ^b   Smith, F ^b,c  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c Osler Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 7 CHLORO 4 HYDROXY 2 (4 METHOXYBENZYL) 3 METHYL 5 PROPYLBENZOFURAN; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 SYNTHESIS INHIBITOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; MACROGOL 8000; PROSTAGLANDIN; TENIDAP; TEPOXALIN; UNCLASSIFIED DRUG; [10 METHOXY 4H BENZO[4,5]CYCLOHEPTA[1,2 B]THIOPHEN 4 YLIDENE]ACETIC ACID;

ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MONOCYTE; NONHUMAN; ORGAN CULTURE; SWINE; SYNOVIUM;

EID: 0029918370     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb05875.x     Document Type: Article

References (35)

1. Belanger, P., Maycock, A., Guidon, Y., Bach, T., Dollob, A. L., Dufresne, C., Ford-Hutchinson, A. W., Gaile, P. H., Hopple, S., Lau, C. K., Letts, L. G., Luell, S., McFarlane, C. S., MacIntyre, E., Meurer, R., Miller, D. K., Piechuta, H., Riendeau, D., Rokach, J., Rouzer, C., Scheigetz, J. (1987) L-656-224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3-methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor. Can. J. Physiol. Pharmacol. 65: 2441-2448
2. Brandwein, S. R. (1986) Regulation of interleukin 1 production by mouse peritoneal macrophages. Effects of arachidonic acid metabolites, cyclic nucleotides, and interferons. J. Biol. Chem. 261: 8624-8632
3. Bray, M A. (1987) Prostaglandins and leukotrienes: fine tuning the immune response. ISI Atlas of Science: Pharmacology 1: 101-106
4. Ciba Geigy Corporation Orientation Brochure (1987) Prinomide. Development Department Ciba Geigy, Summit, New Jersey 07901, USA
5. Coutts, S. M., Khandwala, A., van Inwegen, R., Chakraborty, U., Musser, J., Bruens, J., Jariwala, N., Dally-Meade, V., Ingram, R., Pruss, T., Jones, H., Neiss, E., Weinryb, I. (1985) Arylmethyl phenyl ethers. A new class of specific inhibitors of 5-lipoxygenase. In: Bailey, J. M. (ed.) Prostaglandins, Leukotrienes and Lipoxins. Biochemistry, Mechanisms of Action, and Clinical Applications. Plenum Press, New York, pp 627-637
6. Elford, P. R., Cooper, P. H. (1991) Induction of neutrophil-mediated cartilage degradation by interleukin-8. Arth. Rheum. 34: 325-332
7. Feldman, M., Brennan, F. M., Chantry, D., Haworth, C., Turner, M., Abney, E., Buchan, G., Barrett, K., Barkley, D., Chu, A., Field, M., Maini, R. N. (1990) Cytokine production in the rheumatoid joint: implications for treatment. Ann. Rheum. Dis. 49: 480-486
8. Gillard, J. W., Dixon, R., Ethier, D., Evans, J., Ford-Hutchinson, A. W., Fortin, R., Girard, Y., Guindon, Y., Hamel, P., Jones, T., Leveille, C., Lord, A., Miller, D., Morton, H., Rouzer, C., Yoakim, C. (1992) Therapeutic potential of 5-lipoxygenase inhibitors: the discovery and development of MK-886, a novel mechanism leukotriene inhibitor. In: Rainsford, K. D., Velo, G. P. (eds) Side Effects of Anti-inflammatory Drugs 3. Lancaster Kluwer Academic Publishers, pp 275-286
9. Griffiths, R. J., Pettipher, E. R., Koch, K., Farrell, C. A., Breslow, R., Conklyn, M. J., Smith, M. A., Hackman, B. C., Wimberly, D. J., Milici, A. J., Scampoli, D. N., Cheng, J. B., Pillar, J. S., Pazoles, C. J., Doherty, N. S., Melvin, L. S., Reiter, L. A., Biggars, M. S., Falkner, F. C., Mitchell, D. Y., Liston, T. E., Showell, H. J. (1995) Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 92: 517-521
10. Gordon, R. J., Travis, J., Pruss, T. P , Neiss, E., Muser, J., Chakraborty, U., Jones, H., Leibowitz, M. (1984) In vivo activity of a lipoxygenase inhibitor and a leukotriene antagonist REV 5901-A. IVth Int. Washington Spring Symp. Prostaglandins Leukotrienes, Abst. 266
11. Helle, M., Brakenhoff, J. P J., De Groot, E. R., Aarden, L. A. (1988) Interleukin-6 is involved in interleukin-1 induced activities. Eur. J. Immunol. 18: 957-959
12. Hoffinan, T., Lee, Y. L., Lizzio, E. F., Tripathi, A. K., Jessop, J. J., Taplits, M., Abrahamsen, T. G, Carter, C. S., Puri, J. (1991) Absence of modulation of monokine production via exogenous cyclooxygenase or 5-lipoxygenase metabolites - MK-886 (3-(1-(4-chlorobenzyl)-3-tert-butyl-thio-5-isopropylindol-2-yt]-2,2-diinethyl- propanoic acid), indomethacin, or arachidonate fail to alter immunoreactive interleukin-1beta, or TNF-alpha production by human monocytes in vitro. Clin. Immunol. Immunopathol. 58: 399-408
13. Hopkins, S. J., Humphreys, M. (1989) Simple, sensitive and specific bioassay of interleukin-1. J Immunol. Methods 120: 271-276
14. Hopkins, S. J., Humphreys, M., Jason, M. I. V. (1988) Cytokinesin synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin. Exp. Immunol. 72: 422-427
15. Hopkins, S. J., Holt, I., Humphreys, M. (1990) Removal of inhibitory activity and determination of biologically active interleukin-1 in biological fluids. In: Dinarello, C. A., Kluger, M. J., Powanda, M. C., Oppenheim, J. J. (eds) The Physiological and Pathological Effects of Cytokines. Wiley-Liss, New York, pp 7-12
16. Houssiau, F. A., Devogelaer, J.-P., van Damme, J., de Deuxchaisnes, C. N., van Snick, J. (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritic diseases. Arth. Rheum. 31: 784-788
17. Kaye, J., Porcelli, S., Tite, J., Jones, B., Janeway, C. A. (1983) Both a monoclonal antibody and antisera specific for determinants unique to individual clones helper T cell lines can substitute for antigen and antigen presenting cells. J. Exp. Med. 158: 836-856
18. Koch, A. E., Kunkel, S. L., Burrows, J. C., Evanoff, H. L., Haines, G. K., Pope, R. M., Strieter, R. M. (1991) Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J. Immunol. 147: 2187-2195
19. Kragballe, K. (1989) Topical corticosteroids: mechanisms of action. Acta Derm. Venereol. Suppl. 151: 7-10
20. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275
21. Marshall, L. S., Chang, J. (1989) Novel eicosanoid inhibitors. In: Rainsford, K. D., Velo, G. P. (eds) New Development in Antirheumatic Therapy. Lancaster: Kluwer Academic Publishers, pp 133-151
22. McDonald, B . Loose, L., Rosenwasser, L. J. (1988) The influence of a novel arachidonate inhibitor, CP66,248, on the production and activity of human monocyte IL-1. Arthritis Rheum. 31 (Suppl. 4): 517
23. McMillan, R. M., Bird, T. G. C., Crawley, G. C., Edwards, M. P., Girodeau, J.-M., Kingston, J. F., Foster, S. J. (1991) Methoxy-alkyl thiazoles. a novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase. Agents Actions 34, 110-112
24. Murray, W., Wachter, M., Barton, D., Ferora-Kelly, Y. (1990) The regioselective synthesis of tepoxalin, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-methylpropanamide and related 1,5-diarylpyrazole anti-inflammatory agents. Synthesis 1: 18-20
25. Otterness, I. G., Carty, T. J., Loose, L. D. (1989) Tenidap: a new drug for arthritis. In: Lewis, A. J., Doherty, N. S., Ackerman, N. R. (eds) Therapeutic Approaches to Inflammatory Diseases. Elsevier, Amsterdam, pp 229-241
26. Perreca, E., Reale, M., di Febbo, C., Barbacane, R. C., Castellani, M. C., Cipollone, F., Carratelli, L., Conti, P., Currurollo, F. (1994) Effect of MK-571, a selective leukotriene D4 receptor, antagonist, on smooth muscle cell proliferation and interleukin 1 release. Int. J. Immunopath. Pharmacol. 7: 57-64
27. Pfister, J. R., Ernest, M. J. (1989) Lipoxygenase inhibitors. In: Willis, A. L. (ed.) CRC Handbook of Eicosanoids; Prostaglandins and Related Lipids. Volume II. Drugs Acting via the Eicosanoids. CRC Press, Boca Raton, pp 136-163
28. Rainsford, K. D. (1987) Effects of anti-inflammatory drugs on the release from porcine synovial tissue in vitro of interleukin 1-like cartilage degrading activity. Agents Actions 21: 337-340
29. Rola-Pleszczynski, M. (1988) Leukotriene B4 in T-cell activation. In: Lewis, A., Ackerman, N., Otterness, I. (eds) Advances in Inflammation Research. Vol. 12. Raven Press, New York, pp 91-99
30. Rooney, M., Symons, J A., Duff G. W. (1990) Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol. Int. 10: 217-219
31. Salmon, J. A., Jackson, W. P., Garland, L. G. (1989) Development and in vivo evaluation of 5-lipoxygenase inhibitors: potential drugs for asthma and inflammation. In: Lewis, A. J., Doherty, N. S., Ackerman, N. R. (eds) Therapeutic Approaches to Inflammatory Diseases. Elsevier, Amsterdam, pp 137-149
32. Schnyder, J., Bollinger, P., Payne, T. G. (1990) Inhibition of monokine release by IX 207-887. Agents Actions 29: 108-110
33. Sirios, P., Borgeat, P., Lauzière, M., Dube, L., Rubin, P., Kesterson, J. (1991) Effect of zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents Actions 34: 117-120
34. Thomsen, M. K., Larsen, C. G., Thomsen, H. K., Kirstein, D., Skak-Nielsen, T., Ahnfelt-Ronne, I., Thestrup-Pedersen, K. (1991) Recombinant interleukin-8 is a potent activator of canine neutrophil aggregation, migration and leukotriene B4 biosynthesis. J. Invest. Dermatol. 96: 260-266
35. Zhang, Y., Lin, J.-X., Yip, Y. K., Vilcek, J. (1988) Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin-1 in human fibroblasts: role in the induction of interleukin-6. Proc. Natl. Acad. Sci. USA 85: 6802-6805